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Abstract: In elderly women, loss in bone mass and micro-architectural changes are generally 
attributed to the onset of menopause. Men do not experience menopause, they do, however, 
experience age-related acceleration in bone loss and micro-architecture deterioration. The 
incidence of osteoporotic fractures in elderly men, just as in aged women, increases exponen-
tially with age; the rise in men, however, is some 5–10 years later than in women. Up to 50% 
of male osteoporotics have no identiﬁ  able etiology; however elderly males have much higher 
likelihood of having an identiﬁ  able secondary cause than younger men. Therefore, clinical 
and laboratory evaluation of aged male osteoporotics must be thorough and should be aimed 
at identifying lifestyle or conditions contributing to bone loss and fragility. It is essential to 
identify and treat secondary causes and ensure adequate vitamin D and calcium intake before 
embarking upon treatment with pharmacological agents. The evidence from a limited number 
of trials suggests that bisphosphonates, especially alendronate and risedronate, are effective in 
improving BMD, and seem to be the treatments of choice in aged men with osteoporosis. In 
cases where bisphosphonates are contra-indicated or ineffective, teriparatide or alternatives 
such as strontium should be considered.
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Background
Osteoporosis is a skeletal disorder characterized by compromised bone strength, 
predisposing a person to an increased risk of fracture (NIH 2000). There is a loss of 
bone mass and micro-architectural deterioration of bone tissue, resulting in low bone 
mineral density (BMD). This, in combination with other structural changes, causes 
an alteration in biomechanical properties and an increased risk of low trauma frac-
tures. Osteoporosis is a common condition that afﬂ  icts both men and women, with 
the lifetime risk of fracture at the age of 50 years being estimated at 50% for women 
and 20% for men (Van Staa et al 2001; USDHHS 2004). Up to 20% of symptomatic 
vertebral fractures, 25% of forearm fractures and 30% of hip fractures occur in men 
(Eastell et al 1998; O’Neill et al 2001; Van Staa et al 2001). Furthermore, these frac-
tures have a profound impact on the individual in terms of morbidity and mortality 
(Poor et al 1994, 1995; Center et al 1999; Scane et al 1999; O’Neill et al 2001; Van 
Staa et al 2001).
The number of men presenting with these fractures is rising, because of increasing 
life expectancy and a doubling of the age speciﬁ  c incidence of fractures over the past 
three decades (Boyce and Vassey 1985; Obrant et al 1989; Royal College of Physi-
cians 1989). Therefore, osteoporosis in men is a major health issue and so insights into 
its pathogenesis as well as strategies to prevent and treat it are of importance. Despite 
this, male osteoporosis is both under diagnosed and under treated. In a retrospective 
case-control study in the USA of 1,171 men with osteoporotic fractures, Feldstein et al 
found that only 7.1% received medication for osteoporosis and 1.1% had bone mineral 
measurement (Feldstein et al 2005). Kiebzak et al (2002) found similar results in men 
sustaining low trauma hip fractures, although the rate of treatment did rise to 27% 
between 1 and 5 years later.Clinical Interventions in Aging 2007:2(4) 522
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Low BMD is an established risk factor for osteoporotic 
fractures. The attainment of peak BMD and subsequent 
maintenance is inﬂ  uenced by genetic, endocrine and environ-
mental factors. The peak bone mass is attained in the second 
decade of life and is followed by a period of consolidation 
lasting 5 years, such that peak BMD is achieved in the 
early to mid twenties and maintained until around the age 
of 40 years. Men have larger bones and hence a 10%–12% 
greater peak mass than women. After the age of 35–40 years 
there is a gradual loss of BMD. Women have a rapid phase 
of bone loss following the menopause. Men do not experi-
ence menopause, but they too undergo age-related bone loss. 
Therefore, advancing age is one of the most important risk 
factors for osteoporotic (low trauma) fractures.
Epidemiology of male osteoporosis
The major osteoporotic fractures are those of the vertebral 
body, hip and forearm, but fractures of the humerus, tibia, 
pelvis and ribs are also common. The incidence of most of 
these fractures rises steeply with age in both sexes (Johansen 
et al 1997), but the increase occurs earlier in women than 
men, such that the fracture rate in elderly women is twice 
that of men of the same age (Figure 1).
It has been estimated that as few as 1 in 4 vertebral frac-
tures are clinically recognised (Ensrud et al 1999). Some 
are asymptomatic, but it can also be difﬁ  cult to distinguish 
a vertebral fracture from other causes of back pain and 
vertebral damage including: trauma, degenerative changes, 
Scheuermann’s disease, congenital anomalies, neoplasia, 
infection and Paget’s disease. Furthermore, there are a variety 
of terms and classiﬁ  cation systems used with the expressions 
vertebral fracture, osteoporotic collapse and vertebral defor-
mity often used interchangeably. There is also substantial 
geographical variation in the prevalence of vertebral fracture 
in men across Europe, with the highest rates in Scandinavian 
countries. The European Prospective Osteoporosis Study 
showed an increased incidence of morphometric vertebral 
fractures with age in both sexes (Figure 2), but the rates 
were higher in women than men (Roy et al 2003). The only 
signiﬁ  cant determinant of vertebral fracture incidence in 
men was body mass index (BMI), with reduced risk in those 
with a high BMI.
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Figure 1 The incidence of forearm, symptomatic vertebral and hip fractures in men and women from Cardiff ( Johansen et al 1997).Clinical Interventions in Aging 2007:2(4) 523
Male osteoporosis treatment options
Hip fractures are the most serious consequence of osteo-
porosis as they have the most severe impact in terms of mor-
bidity and mortality and result in huge costs for health and 
social services. In the USA, hip fractures cost $15 billion in 
1998 and results in 60,000 admissions to nursing homes annu-
ally (Seeman 2001). The incidence of hip fractures increases 
exponentially with age in both sexes in all geographical areas 
and ethnic groups (Johansen et al 1997; Figure 1). There is 
a greater difference in hip fracture incidence between ethnic 
groups and countries than between sexes, highlighting the 
potential importance of environmental, genetic and lifestyle 
factors in the etiology of hip fractures. The highest incidence 
of hip fracture is in Scandinavia, with the lowest rates in 
Mediterranean countries (Pande and Francis 2001).
Low trauma distal forearm fracture is widely regarded as 
a typical early manifestation of post-menopausal osteoporosis 
in women (Eastell 1996; Cuddihy et al 1999). Indeed, 50% of 
women who suffer a distal forearm fracture of Colles’ type 
will have osteoporosis (Earnshaw et al 1998). Traditionally, 
this has not been thought to be the case for men. This is partly 
because the incidence of these fractures is much lower in 
men than in women at 9 per 10000 person years as opposed 
to 36.8 per 10000 person years (O’Neill et al 2001) and does 
not increase with age in the same way. It has been suggested 
(Eastell 1996) that this is because men have a higher peak 
bone mass at this site than women and have no decrease 
in distal forearm BMD with age. In normal men Butz et al 
(1994) found a rate of trabecular bone loss of 0.59%/year at 
the forearm and a similar rate of loss was found by Berntsen 
et al 2001. The incidence of forearm fracture does rise in 
the very old (O’Neill et al 2001). Furthermore, low femoral 
neck bone density has been demonstrated to be a major risk 
factor for forearm and wrist fractures in men, along with 
height loss, dietary calcium and history of falls (Nguyen et al 
2001). Cuddihy et al 1999 have shown that men have a 2.7 
fold and a 10.7 fold increase in hip and vertebral fractures 
respectively following a distal forearm fracture. Finally, in 
a case-control study, 41.8% of men sustaining distal forearm 
fractures were found to be osteoporotic in at least one site 
(Tuck et al 2002); this is comparable to that seen in women 
with distal forearm fractures (Earnshaw et al 1998).
Morbidity and mortality
There is considerable disability after hip fracture in men, with 
only 21% living independently in the community a year later, 
whereas 26% receive home care and 53% live in an institution 
(Poor et al 1995). Although not all vertebral fractures come 
to medical attention, symptomatic fractures typically cause 
acute episodes of back pain, which usually settle after 6–8 
weeks. Men with symptomatic vertebral fractures commonly 
complain of back pain, loss of height and kyphosis, but also 
have signiﬁ  cantly less energy, poorer sleep, more emotional 
problems and impaired mobility than age-matched control 
subjects (Scane et al 1999).
There is an increased mortality after all major fracture in 
men and women, with much of the excess mortality occurring 
in the ﬁ  rst year. This excess mortality is higher in men than 
it is in women (Figure 3). The standardized mortality ratio 
after a hip fracture is 3.17 in men and 2.18 in women and 
for vertebral fractures this is 2.38 and 1.66 respectively, but 
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Figure 2 The incidence of morphometric vertebral fractures in men and women in the European Prospective Osteoporosis Study (Roy et al 2003).Clinical Interventions in Aging 2007:2(4) 524
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the reason for the higher mortality in men remains uncertain 
(Center et al 1999). One possibility is that this may be due 
to a higher prevalence of co-existing conditions, which are 
associated with an increased risk of fracture and mortality.
Pathogenesis of low trauma 
fractures in men
The risk of fracture is determined by skeletal and non-skeletal 
risk factors. The skeletal risk factors include BMD, bone 
turnover, trabecular architecture, bone size, and skeletal 
geometry, whereas non-skeletal risk factors include postural 
instability and propensity for falling. There is an inverse 
relationship between BMD and the incidence of vertebral 
and hip fractures in men (Figure 4), which is similar to that 
observed in women (De La et al 1997; Van der Klift et al 
2002). Case-control studies show that men with distal fore-
arm, symptomatic vertebral and hip fractures have lower 
BMD than age-matched control subjects (Scane et al 1999; 
Pande et al 2000; Tuck et al 2002) (Figure 5); therefore, lower 
BMD is associated with an increased risk of fracture.
Non-skeletal risk factors (falls)
A number of studies, mainly in women, show that the risk 
of fracture is determined not only by BMD and other skel-
etal factors, but also by non-skeletal factors associated with 
physical frailty and an increased risk of falls (Cummings et al 
1995; Dargent-Molina et al 1996). A prospective study from 
Australia showed that the combination of low BMD and high 
body sway conferred a greater risk of fracture than either 
one alone (Nguyen et al 1993). In the same study, there was 
also an increased risk of fracture with quadriceps weakness, 
falls in past year, previous fractures, low body weight and 
short stature. In men and women the risk of hip fractures is 
also increased by conditions predisposing to falls, such as 
strokes, Parkinsonism, dementia, vertigo, alcoholism and 
visual impairment (Grisso et al 1991; Poor et al 1995).
Secondary causes
Osteoporosis may be either primary (idiopathic) or sec-
ondary to one of a number of identiﬁ  able causes. In either 
case the end result is a low BMD and a propensity for low 
trauma fractures. The development of osteoporosis may be 
accelerated by underlying secondary causes of bone loss 
such as hypogonadism and steroids, which are found in over 
50% of men presenting with symptomatic vertebral crush 
fractures (Baillie et al 1992). A case-control study from the 
Mayo Clinic investigated 105 men with vertebral fractures 
and 105 age-matched control subjects with Paget’s disease 
of bone. This showed a signiﬁ  cantly increased relative risk 
of vertebral fractures with smoking, alcohol consumption 
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Figure 3 The Age-Standardised Mortality Ratio after fractures in men and women (Center et al 1999).Clinical Interventions in Aging 2007:2(4) 525
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and underlying secondary causes of osteoporosis, whilst the 
risk was reduced in the presence of obesity (Seeman et al 
1983). A subsequent case-control study from Newcastle has 
demonstrated an increased risk of vertebral fractures with 
oral steroid therapy, anticonvulsant treatment, smoking, 
alcohol intake 20 units/week, physical inactivity and low 
free androgen index (Scane et al 1999). Case-control studies 
of hip fractures in men have also shown an increased risk 
of fracture with disorders associated with secondary osteo-
porosis (Stanley et al 1991). The major secondary causes of 
osteoporosis in men are given in Table 1.
Diagnosis of male osteoporosis
The use of bone density measurement
Until the development of DXA the diagnosis of osteoporosis 
in men was based on the history of fractures after minimal 
trauma. The introduction of DXA bone density measurement 
allowed a more objective diagnosis of osteoporosis and 
stimulated interest in making the diagnosis before fractures 
occur. The World Health Organization (WHO) has deﬁ  ned 
osteoporosis as a BMD 2.5 standard deviations or more below 
the mean value for young adults (T score  –2.5), but this 
has only been established for women.
Although the reference ranges for BMD measurements 
in men are derived from a smaller sample size than in 
women, there is a similar inverse relationship between abso-
lute BMD and the incidence of vertebral and hip fractures 
in both sexes (De Laet et al 1997; Van der Klift et al 2002). 
This indicates that the same threshold value of absolute 
BMD could be used for the diagnosis of osteoporosis in 
men and women. A T score of –2.5 in women would there-
fore be equivalent to a T score of –2.8 in men, calculated 
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Figure 4 The relationship between femoral neck BMD and the incidence of hip fractures in 80 year old men and women in the Rotterdam Study (De Laet et al 1997).
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using gender speciﬁ  c normative data. The prevalence of 
osteoporosis in men using this diagnostic threshold is too 
low, whereas the prevalence of T score –2.5 at the hip, 
spine or forearm in men over the age of 50 years is broadly 
comparable to the lifetime risk of fractures at these sites 
(Melton et al 1998). This suggests that the WHO criteria 
may be applicable for the diagnosis of osteoporosis in men 
and women. More recently, De Laet et al (2002) using math-
ematical models and data from a large prospective study in 
Rotterdam, concluded that using male speciﬁ  c T score of 
–2.5 best ﬁ  tted the available data. The International Society 
for Clinical Densitometry Position Development (ISCD) 
Panel and Scientiﬁ  c Advisory Committee also came to 
this conclusion in 2002 and is contained in their ofﬁ  cial 
positions statement 2005 (Binkley et al 2002). The ISCD’s 
ofﬁ  cial positions have been endorsed by the American 
Society for Bone and Mineral Research (ASBMR) and the 
International Osteoporosis Foundation.
Although only about 50% of men with apparently low 
trauma vertebral fractures have densitometric evidence of 
osteoporosis at the lumbar spine or femoral neck, a further 
40% have osteopenia (Scane et al 1999). It has therefore 
been suggested that treatment for osteoporosis should 
be considered in men with low trauma vertebral or hip 
fractures and evidence of osteoporosis or osteopenia at 
the lumbar spine or femoral neck, whereas the possibility 
of unrecognized antecedent trauma should be explored 
in those with normal bone density measurements (Tuck 
and Francis 2006).
The fact that only 50% of men are osteoporotic according 
to BMD measurements by DXA may be partly due to the 
uncertainties of threshold values for osteoporosis in men. 
It may also reﬂ  ect that other aspects of size, structure and 
geometry may be important in determining fracture risk.
Investigation of osteoporosis in men
Secondary causes of osteoporosis should be sought by care-
ful history, physical examination and appropriate investi-
gation (Table 2). Serum testosterone should be measured 
in a morning sample, because of the diurnal variation in 
circulating concentration. A recent hip fracture may alter the 
hypothalamic–pituitary gonadal axis, as well as increasing 
the alkaline phosphatase, so investigations for secondary 
osteoporosis should be performed after the patient has recov-
ered from the fracture and subsequent surgery.
Prostate speciﬁ  c antigen should also be measured in 
men with vertebral fractures and symptoms of prostatism or 
evidence of sclerosis on x-rays. In elderly men with osteo-
porosis, serum 25 hydroxyvitamin D (25OHD) and intact 
parathyroid hormone (PTH) measurements may be used to 
exclude vitamin D insufﬁ  ciency and secondary hyperpara-
thyroidism (Al-oanzi et al 2006).
These investigations are usually normal in men with 
idiopathic osteoporosis, apart from a transient rise in serum 
alkaline phosphatase after fracture. The most frequently 
encountered causes of secondary osteoporosis in men are 
oral steroid therapy, hypogonadism, alcohol abuse, myeloma 
and skeletal metastases. In men with severe unexplained 
osteoporosis, it may be worthwhile considering 24-hour urine 
calcium estimation to identify hypercalciuria, 24-hour urine 
cortisol to exclude Cushing’s syndrome and anti-endomysial 
antibodies to look for coeliac disease. Although up to 50% 
of male osteoporotics may have no identiﬁ  able etiology, 
elderly males have much higher likelihood of having identiﬁ  -
able secondary cause than younger men. The younger male 
osteoporotics have been shown to have several and varied 
possible secondary causes (Varanasi et al 1999).
Management of osteoporosis in men
The management of osteoporosis should include symptom 
relief, lifestyle measures to prevent bone loss and decrease 
the risk of falls and speciﬁ  c treatment to increase BMD 
and reduce the incidence of fractures. All patients should 
be offered analgesia of potency appropriate for the severity 
of their pain. Transcutaneous electrical nerve stimulation 
(TENS) is also of value in some patients with vertebral 
fractures. For persistent pain there is now the option of ver-
tebroplasty or kyphoplasty, where this technique is available. 
Advice from a physiotherapist may help to maintain mobility 
and prevent falls, as may occupational therapy assessment. 
Table 1 Causes of secondary oeteoporosis in men
Major causes with Hypogonadism
strong evidence Alcoholism
 Corticosteroids
 Transplantation
Other causes Hormonal  -  hyperparathyroidism 
   -  thyrotoxicosis
 Gastric  surgery
  Gastrointestinal disorders  - celiac disease
   -  inﬂ  ammatory bowel
     disease
    - liver disease
 Drugs  -  anticonvulsants
   -  warfarin
 Idiopathic
 hypercalciuria
 Malignancy
 ChemotherapyClinical Interventions in Aging 2007:2(4) 527
Male osteoporosis treatment options
Advice and support is also available from self-help groups 
such as the National Osteoporosis Society (http://www.nos.
org.uk).
Men with osteoporosis should be given advice on lifestyle 
measures to decrease bone loss, including a balanced diet rich 
in calcium, weight bearing exercise, cessation of smoking, 
moderation of alcohol intake and maintenance of regular 
exposure to sunlight in summer months. Where there is a 
history of recurrent falls, falls assessment and multifactorial 
intervention strategies may decrease the risk of falls. Hip 
protectors may potentially decrease the risk of hip fractures in 
frail elderly patients with recurrent falls, although compliance 
with their use is poor.
Treatment of osteoporosis in men
Any underlying secondary cause of osteoporosis should be 
treated if possible, as speciﬁ  c treatment of underlying con-
ditions such as hyperthyroidism, hypogonadism and hyper-
parathyroidism may increase bone density by 10%–20%. 
There are a number of therapeutic options for idiopathic 
osteoporosis in men, including bisphosphonates, teriparatide, 
calcitonin and calcium and vitamin D supplementation. The 
best data are available for alendronate and teriparatide: Table 
3 summarizes the data for the available treatments.
Established treatments
The established treatments for osteoporosis can be divided, 
based on underlying molecular physiology, into two broad 
biological categories: anabolic agents that directly stimu-
late bone formation and antiresoptive agents that inhibit 
osteoclast-mediated bone resorption. Both these agents 
increase BMD and reduce fracture risk. The extent of fracture 
risk of reduction with antiresoptives is rarely greater than 
50% of the baseline risk (Rosen and Billzekian 2001). The 
antiresorptives, such as bisphosphonates, calcitonin, testos-
terone in men and estrogen for women, reduce remodeling 
and prolong mineralization duration. Anabolic agents, such 
as parathyroid hormone and strontium, directly stimulate 
bone formation.
Bisphosphonates
Bisphosphonates (BPs) are widely used as antiresorptive 
agents for the treatment of osteoporosis as well as other 
metabolic bone diseases, including Paget’s disease, and 
tumor-associated bone disease. All BPs are synthetic pyro-
phosphates an analog, ie, oxygen in P-O-P has been replaced 
by a carbon, resulting in a P-C-P backbone structure. They 
have a high afﬁ  nity for bone mineral and are resistant to 
chemical and enzymatic hydrolysis. Two additional chains 
(R1 and R2, respectively) have been modiﬁ  ed to produce 
different pharmacological properties and potencies (Table 4). 
The antiresoptive action of bisphosphonates is thought to 
result from their ability to bind strongly to bone and sup-
press osteoclast-mediated bone resorption. At higher doses 
however most BPs can inhibit normal mineralization and 
therefore the relative potency of a particular BP is given as a 
ratio of its antiresoptive activity to its normal mineralization 
inhibitory action. The relative potency is a function of the 
chemical structure, especially of the R1 and R2 chains. The 
newer compounds have a higher relative potency, as a result 
of which their relative risk of inhibiting bone mineralization 
leading to osteomalacia is lower.
Table 2 Investigations for secondary osteoporosis in men
Investigation Finding  Possible  Cause
Full blood count  Anemia  Neoplasia or malabsorption
  Macrocytosis  Alcohol abuse or malabsorption
ESR Raised  ESR  Neoplasia 
Biochemical proﬁ  le  Hypercalcemia  Suppressed TSH; high T4 or T3
  Abnormal liver function  Alcohol abuse or liver disease
  Persistently high AP  Skeletal metastases
Thyroid function tests  Suppressed TSH; high T4 or T3 Hyperthyroidism
Serum and urine immunoelectrophoresis  Paraprotein band  Myeloma
Testosterone, SHBG, LH, FSH  Low testosterone or free testosterone  Hypergonadotrophic hypogonadism with
 index raised  gonadotrophins
    Hypogonadotrophic hypogonadism with
   low  gonadotrophins
Prostate speciﬁ  c antigen  Raised levels (often markedly so)  Skeletal metastases from prostate cancer
Vitamin D  Low  Osteomalacia
PTH  High  Primary or secondary hyperparathy-
   roidism
Anti-endomysial antibodies  Positive  Celiac diseaseClinical Interventions in Aging 2007:2(4) 528
Tuck and Datta
BPs have become the treatment of choice for most men 
with osteoporosis, following the publication of a large, ran-
domized control trial of oral alendronate. This compared the 
effect of two years’ treatment with 10 mg daily alendronate 
(Fosamax) and placebo in 241 men with osteoporosis aged 
between 31 and 87 years, 36% of whom were hypogonadal 
(Orwoll et al 2002). This showed signiﬁ  cant improvement 
in lumbar spine and femoral neck BMD with alendronate 
(Figure 6), with similar increases in BMD in eugonadal and 
hypogonadal men. There was also a signiﬁ  cant reduction in 
vertebral fracture incidence and decrease in height loss with 
alendronate. Similar results were reported by two other RCTs: 
one in 134 men with primary osteoporosis and another with 77 
men (Gonelli et al 2003). The daily preparation of alendronate 
has now been licensed in the UK for the treatment of osteopo-
rosis in men. There is no reason to think that the 70 mg weekly 
preparation would not be equally effective and many patients 
ﬁ  nd the weekly preparation more convenient.
Observational studies in men with idiopathic and second-
ary osteoporosis suggest that intermittent cyclical etidronate 
therapy (Didronel PMO) increases BMD at the lumbar 
spine by 5%–10%, with smaller increases at the hip. In an 
uncontrolled study in 42 men with vertebral fractures, cycli-
cal etidronate increased spine BMD by 3% annually, whilst 
hip bone density showed a non-signiﬁ  cant rise of 0.7% per 
year (Anderson et al 1997). It would therefore appear that 
cyclical etidronate has comparable effects on bone density 
in men and women, although the effect on fracture incidence 
in men remains unclear.
Although there are no published studies of the effect of rise-
dronate (Actonel) in men with idiopathic osteoporosis, there is 
no reason to suspect that it would be ineffective, particularly 
as it has been shown to be beneﬁ  cial in men and women 
with glucocorticoid-induced osteoporosis. Furthermore, data 
from Ringe et al (2004) have demonstrated that there was 
a signiﬁ  cant increase in BMD and a 60% reduction in new 
vertebral fractures after 1 year of treatment with risedronate in 
osteoporotic men, but this has only been published in abstract 
form. As risedronate has considerable evidence for increasing 
BMD and reducing fracture rates in women it is probably the 
second choice bisphosphonate after alendronate.
Further evidence that bisphosphonates are equally effective 
in men and women is provided by a three year RCT in 677 
men and women with osteoporosis and at least one vertebral 
fracture. There were 84 men randomized to receive clodronate 
or placebo (McCloskey et al 1999). Interim analysis at one 
year showed a signiﬁ  cant increase in lumbar spine and total 
Table 3 Summary of the available evidence for treatments of male osteoporosis (A = randomised controlled trials, B = other well 
designed studies, C = expert opinion/reports)
Treatment  Increase in BMD  Reduction in  Reduction in  Reduction in
  (spine and/or hip)  vertebral fractures  hip fractures  non-vertebral
       fractures
Alendronate A  A  None  None
Etidronate B  None  None  None 
Risedronate C  None  None  None
Pamidronate C  C  None  None
Ibandronate C    None  None
Clodronate A  A  None  None
Teriparatide A  A  None  None
Calcium and  A (older men)  None  None  None
vitamin D
Calcitonin A  None  None  None 
Strontium C  None  None  None
Androgens B  None  None  None
Table 4 Relative potencies of bisphosphonates
Bisphosphonates  Side Chains R1, R2  Relative Potency
Etidronate R1=  -OH  1
 R2=  -CH3
Clodronate R1=  -Cl  10
 R2=  -Cl
Pamidronate R1=  -OH  100
 R2=  -C2H4NH2
Alendronate R1=  -OH  500
 R2=  -C3H6NH2
Risedronate R1=  -OH  1000
 
 R2=
Ibandronate R1=  -OH  10000
 R2=  -C2H4N(CH3)C5H11
Zoledronate R1=  -OH  100000
 
 R2=Clinical Interventions in Aging 2007:2(4) 529
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hip BMD with clodronate compared with placebo, with similar 
changes in men and women. There was also an overall reduc-
tion in vertebral fracture incidence with clodronate.
Intravenous BPs are unlicensed for the treatment of osteo-
porosis, but are nevertheless widely used in patients unable 
to tolerate oral BPs. There have been few published studies 
of intravenous BPs and none solely in men or demonstrat-
ing antifracture efﬁ  cacy. One abstract showed a signiﬁ  cant 
increase in lumbar spine BMD in men 12 months after 30 mg 
of intravenous pamidronate given at monthly intervals 
(Tuck and Fordham 2001). Miller et al demonstrated that IV 
pamidronate (30 mg every three months) produced similar 
response rates to standard therapy with oral BPs (Miller et 
al 2005). Adverse events were uncommon and included 
myalgias and ﬂ  u-like symptoms. In a small, pilot study of 
14 men with idiopathic osteoporosis intravenous ibandronate 
produced a signiﬁ  cant 6.7% increase in lumbar spine BMD 
in combination with calcium and vitamin D supplementa-
tion (Lamy et al 2003). There were also signiﬁ  cant falls in 
bone turnover markers (beta crosslinks and osteocalcin) of 
30%–45%. Ibandronate is also available orally as monthly 
and 3 monthly preparations and increases BMD and reduces 
fractures in women, but there are no data available in men. 
Zoledronate is a potent bisphosphonate, which need only 
given as an infusion annually, but there is no data in men 
except for those with cancer. The less frequent dosing offered 
by ibandronate and zoludronate is likely to increase compli-
ance, but anti-fracture evidence is required.
Oral BPs have to be taken during fasting and food must 
has be avoided for at least thirty minutes after alendronate or 
risedronate. This is necessary as the gastrointestinal absorp-
tion of orally administered BPs is poor, and the absorption 
can be almost totally abolished by simultaneous ingestion 
with food, divalent cations and certain medication. Therefore, 
many of the elderly patients who may also be taking iron or 
calcium supplements should avoid taking BPs at same time 
as any of these medications.
Oral BPs also need to be taken either sat upright or stand-
ing and are contraindicated in patients with impaired esopha-
geal emptying. This contraindication is to avoid esophageal 
erosion, which is one of the most serious side effects of oral 
BPs. This is particularly so for the amino-bisphosphonates 
and these should be avoided in patients with peptic ulcers 
and reﬂ  ux esophagitis. Parental administration can cause 
acute hypocalcemia, but this is rarely seen in oral therapy. 
However, alendronate and risderonate may cause mild 
hypocalcemia and hypophosphatemia, and increase PTH 
and worsen hyperparathyroidism. There have been reports 
of non-speciﬁ  c renal damage by BPs, but that is only seen 
with high doses. BPs should therefore be used cautiously in 
patients with renal insufﬁ  ciency.
Teriparatide
Teriparatide is a recombinant fragment of human parathy-
roid hormone (PTH) composed of 1–34 amino acids and 
has anabolic properties, which make it useful for treating 
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osteoporosis in men. PTH stimulates both bone formation 
and resorption, leading to increased or decreased BMD, 
depending on the mode of administration. Continuous 
infusion causes persistent elevation of PTH and results in 
greater resorption than formation, leading to bone loss. In 
contrast, daily injections of PTH lead to only transient peaks 
in serum PTH, resulting in greater bone formation and an 
increase in BMD.
In postmenopausal women with prior vertebral fractures, 
teriparatide increases BMD and reduces both vertebral and 
non-vertebral fractures (Neer et al 2001). In a small study 
of subcutaneous rhPTH (1–34) 400 IU daily in 23 men aged 
30–68 years, BMD increased by 13.5% in the lumbar spine 
and by 2.9% at the femoral neck over 18 months (Kurland 
et al 2000). Another study in 437 osteoporotic men, showed 
signiﬁ  cant increases in lumbar spine and femoral neck 
after a median of 11 months’ treatment with subcutaneous 
teriparatide 20 and 40 μg daily (Orwoll et al 2003: Figure 7). 
Kaufman et al 2005 continued to observe 355 of these men 
over a period of 30 months and found that BMD gradually 
fell after cessation of teriparatide, but remained signiﬁ  cantly 
higher than that at baseline. The rate of new vertebral frac-
ture was also signiﬁ  cantly reduced by 51%. Given the fall in 
BMD after stopping teriparatide, the question remained as to 
whether BPs would increase the BMD if given in combina-
tion or stop the fall if given after teriparatide. Kaufman et al 
in their observational study found that those men given BPs 
after teriparatide maintained their BMD and tended towards 
further increases. Kurland et al (2004) reported an obser-
vational study of 21 men and also reported that there were 
signiﬁ  cant increases in lumbar spine BMD if BPs were given 
after cessation of teriparatide. Recently, a trial was reported 
in which 83 men were randomized to receive alendronate or 
teriparatide alone or in combination. Those given teriparatide 
alone had signiﬁ  cantly greater BMD than either of the other 
two groups (Finkelstein et al 2003) It therefore appears that 
BPs should be given after teriparatide to maintain the BMD, 
but not used in combination as they attenuate the effects 
of teriparatide. Side effects of teriparatide include nausea, 
headache and transient mild hypercalcaemia, but these were 
reported less commonly with the 20 μg dose. Teriparatide 
has therefore been licensed for use at a recommended dose 
of 20 μg daily for an 18 month course of treatment.
In Europe, teriparatide is licensed for a treatment course 
of 18 months and in the USA for 24 months. Teriparatide is 
contraindicated in patients with Paget’s disease of bone and 
unexplained elevation of alkaline phosphatase, as they are 
considered to be at an increased baseline risk for osteosar-
coma. It should not be used in patients with metabolic bone 
disease other than osteoporosis, such as hypercalcemia or 
metastatic bone metastases. The British Society for Rheuma-
tology also recommends caution in ankylosing spondylitis, 
diffuse idiopathic skeletal hyperostosis (DISH), lumbar canal 
stenosis, urolithiasis and gout.
Administration of 20 μg dose of teriparatide leads to 
transient hypercalcemia, which is seen approximately 2 hours 
after the dose and reached maximum between 4 to 6 hours. 
Neer et al observed mild hypercalcemia, deﬁ  ned as total 
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calcium of 10.6 mg/dL, in 11% of women receiving 20 
μg dose of teriparatide (Neer et al 2001). Transient episodes 
of orthostatic postural hypotension are one of the infrequent 
adverse effects of teriparatide. This typically occurred in 
the ﬁ  rst several doses and within 4 hours of the dose being 
administered. The transient orthostatic hypotension resolved 
within a few minutes to a few hours and did not preclude 
use of the treatment. Other adverse side effects associated 
with teriparatide administration include nausea, headache, 
angina pectoris, constipation, depression, dizziness, insom-
nia, hypertension, and syncope. There is insufﬁ  cient data to 
assess the safety of teriparatide in patients with compromised 
cardiac, hepatic or renal function.
Calcium and vitamin D
The role of calcium and vitamin D supplementation in the 
management of osteoporosis in men remains unclear. In an 
RCT in 86 normal men aged 30–87, supplementation with 
1,000 mg calcium and 1,000 IU of vitamin D daily had no 
effect of bone loss from the forearm or spine (Orwoll et al 
1990). In contrast, an American RCT in 389 older men and 
women (mean age 70 years) living at home demonstrated 
that 700 IU vitamin D3 and 500 mg elemental calcium daily 
had a modest beneﬁ  cial effect on bone density and decreased 
the incidence of non-vertebral fractures (Dawson-Hughes 
et al 1997). Sub-group analysis of the results for the men in 
this study showed a signiﬁ  cant improvement in BMD with 
calcium and vitamin D, but no reduction in fractures was 
demonstrated. A recent study of oral vitamin D3 100,000 IU 
every 4 months in 2,037 men and 649 women, aged between 
65 and 85 years living in the community, showed an overall 
22% reduction in fracture risk (Trivedi et al 2003). There 
was no signiﬁ  cant reduction in fractures at any speciﬁ  c site 
or in either gender alone. In the absence of more conclu-
sive studies, it seems reasonable to recommend calcium 
and vitamin D in frail elderly men, who are likely to have 
vitamin D deﬁ  ciency and secondary hyperparathyroidism. 
Calcium and vitamin D may also be used as an adjunct to 
other treatments in men with established osteoporosis. It is 
important to ensure adequate calcium and vitamin D intake 
before commencing antiresorptive or anabolic treatment for 
osteoporosis, this is essential to derive optimum beneﬁ  t and 
to prevent and mitigate some of the possible adverse side 
effects of the therapies.
Calcitonin
Calcitonin, a 32 amino acid peptide, is the most powerful 
physiological inhibitor of the osteoclast activity. It also 
inhibits tubular reabsorption of calcium and phosphate, lead-
ing to increased rates of their loss in urine. These functions 
in regulating calcium and phosphate metabolism make it 
a potentially useful treatment for osteoporosis. Intranasal 
salmon calcitonin formulations miacalcin and fortical were 
approved by the FDA in 1995 and in 2005 respectively and 
there is some data for its use in men.
A small study in 28 men with osteoporosis showed that 
nasal calcitonin 200 units daily for 12 months increased 
lumbar spine BMD by 4.7% compared with control subjects 
(Figure 8), but resulted in no signiﬁ  cant change in BMD at 
the proximal femur (Trovas et al 2002). A larger random-
ized control trial has subsequently been performed with 
71 men suffering idiopathic osteoporosis, which demon-
strated signiﬁ  cant increases in both lumbar spine and femoral 
neck BMD of 3.5% and 3.2% respectively compared with 
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controls (Toth et al 2005). There is, however, no anti-fracture 
evidence as yet in men. Calcitonin may also be useful in the 
management of the patient with acute vertebral fracture. 
An RCT in 32 men and 68 women with acute vertebral 
fracture showed that intranasal calcitonin 200 iu daily for 
28 days was more effective than placebo at decreasing pain 
and improving mobility (Lyritis et al 1997). The common 
adverse drug reactions associated with injectable calcitonin 
include nausea and ﬂ  ushing, but these occur less frequently 
in patients treated with nasal spray.
Alternative agents
Strontium
Strontium ranelate is now an established treatment for post-
menopausal osteoporosis. It is a novel agent and a new class 
of drug having a dual action. It both stimulates bone forma-
tion and suppresses bone resorption. It increases BMD at the 
lumbar spine and hip by 14.4 and 8.3% respectively after three 
years, although at least half of this increase is the result of the 
incorporation of metal into bone rather than its effect on bone 
mineralization (Meunier et al 2004). It also reduces rates of 
vertebral and non-vertebral fractures, as well as hip fracture in 
those at high risk (Meunier et al 2004; Reginster et al 2005). 
However, there is no data available for men. Nevertheless, 
there is no reason to think that it would not work in men and 
may therefore be worth consideration when BPs fail.
Strontium ranelate is associated with mild adverse effects, 
such as transient nausea, diarrhea and creatine kinase eleva-
tions. There is an increased incidence of deep vein thrombosis 
and pulmonary embolism associated with strontium admin-
istration and it should so be used with caution in patients at 
increased risk of venous thromboembolism.
Androgens
In addition to improving bone density in men with hypo-
gonadal osteoporosis (Behre et al 1999), testosterone may 
increase spine bone density in eugonadal men with vertebral 
fractures and there have been a number of small studies. An 
uncontrolled study of testosterone treatment in 21 eugonadal 
men with vertebral osteoporosis showed a signiﬁ  cant increase 
in spine bone density of 5% in six months, but no change 
in hip bone density was seen (Anderson et al 1997). During 
treatment there was a 48% increase in serum testosterone, 
and a 22% reduction in SHBG, leading to an 88% increase 
in free androgen index. Serum estradiol also increased by 
41%. The biochemical markers of bone turnover showed 
a reduction in bone formation and resorption. Analysis of 
the changes in bone density and sex steroid concentrations 
showed a closer relationship between the changes in BMD 
and serum estradiol than with serum testosterone.
Another small, randomized control trial in 86 osteopopro-
tic men examined the effects of oral dehydroepiandrosterone 
(DHEAS) over a 6 month period. As expected there were 
signiﬁ  cantly higher concentrations of DHEAS and IGF-1 
(insulin-like growth factor one) in the treatment group. How-
ever, DHEAS had only modest effects on BMD of between 
2.32 and 3.1%. There were no signiﬁ  cant changes in free 
testosterone, estradiol or PSA (Sun et al 2002). A random-
ized controlled crossover study in 15 men on long-term 
glucocorticoid treatment showed an increase in spine bone 
density of 5% after 12 months treatment with testosterone, 
whilst no change was observed during the control period of 
12 months observation (Reid et al 1996). Side effect and 
cardiovascular risk factor proﬁ  les were acceptable in these 
small studies, but androgen treatment needs to be more fully 
explored in a multicentre randomized controlled trial. Until 
the results of such studies are available this treatment should 
also be regarded as experimental.
Calcitriol
Calcitriol, also known as 1,25 dihydroxyvitamin D, is the 
hormonally active metabolite of vitamin D. Calcitriol pro-
motes calcium absorption from the bowel and may stimulate 
osteoblastic new bone formation. In a small RCT in 41 men 
with idiopathic osteoporosis, there was no difference in the 
change in spine or femoral neck BMD between those treated 
with calcitriol and the control group taking calcium supple-
ments (Ebeling et al 2001).
Fluoride salts
Fluoride salt therapy, mainly as sodium ﬂ  uoride, has been 
used for over thirty years to treat osteoporosis. Fluoride is 
believed to reduce risk of fracture by increasing bone mass 
and by reducing bone loss. Although ﬂ  uoride has an ability to 
increase BMD at lumbar spine, it does not result in a reduction 
of vertebral fractures. In increasing the dose of ﬂ  uoride, one 
increases the risk of non-vertebral fracture and gastrointes-
tinal side effects without any effect on the vertebral fracture 
rate. (Haguenauer et al 2000) Some clinical trials of ﬂ  uoride 
have included men, but it is difﬁ  cult to ascertain whether 
responses were in any way gender-speciﬁ  c. A German RCT 
shows that low dose intermittent monoﬂ  uorophosphate and 
calcium increases bone density and decreases the risk of ver-
tebral fractures in men with osteoporosis (Ringe et al 1998). 
On current evidence ﬂ  uoride salts cannot be recommended 
for the treatment of osteoporosis.Clinical Interventions in Aging 2007:2(4) 533
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Emerging novel therapies
Recent advances in the understanding of the functioning 
and regulation of osteoblast and osteoclast activity has led 
to the development of a number of novel therapies for the 
treatment of osteoporosis.
RANKL modulator
Receptor activator of nuclear factor NF-κβ ligand (RANKL) 
is essential for osteoclast differentiation and activity. It acts 
by binding to RANK expressed on osteoclast precursors 
stimulating their differentiation into mature osteoclasts. The 
human monoclonal antibody denosumab, previously known 
as AMG 162, speciﬁ  cally binds and inhibits RANKL activ-
ity. Denosumab mimics osteoprotegerin, which is a soluble 
RANKL decoy receptor that binds RANKL. Osteoprotegrin 
is the key endogenous regulator of the RANKL–RANK path-
way. Preliminary evaluation, over a period of 12 months in 
412 postmenopausal women with low bone mineral density, 
suggests that denosumab might be an effective treatment for 
osteoporosis (McLung et al 2006). However, further studies 
are needed to determine its efﬁ  cacy as well as any potential 
side effects (Schwartzmann et al 2006).
Intact human recombinant PTH (1-84)
Intact human recombinant PTH (1-84) is also under evalua-
tion as an anabolic therapy for the treatment of osteoporosis. 
The anabolic effect on BMD and fracture reduction, as well 
as adverse effects of the full-length PTH and of the truncated 
1-34 N-terminal form (teriparatide) appears to be comparable 
(Hodsman et al 2003). Further studies are needed to conﬁ  rm 
this observation and to assess the relative efﬁ  cacy of the two 
formulations in both women and men.
SERMs
SERMs (Selective Estrogen Receptor Modulators) are 
non-hormonal agents that modulate the estrogen recep-
tors in some speciﬁ  c tissues. SERMs can have agonist or 
anatagonist action, ie, mimicking or inhibiting estrogen 
respectively. This will vary from tissue to tissue and the 
design of the agent. For example, raloxifene inhibits estro-
gen receptors in breast and reduce the risk of breast cancer, 
but stimulate estrogen receptors in bone improving BMD. 
Raloxifene has been approved for the prevention and treat-
ment of postmenopausal osteoporosis (Ettinger et al 1999). 
Pathophysiological considerations suggest that it may 
also be effective in particular cases of male osteoporosis. 
However, large scale clinical trials are required to assess 
their use in men.
Anabolic steroids
Although agents such as nandrolone decanoate increase bone 
density transiently in men with osteoporosis, the beneﬁ  t may 
be lost in the longer term, possibly because of suppression 
of the pituitary-gonadal axis, with consequent reduction in 
endogenous sex hormone production (Hamdy et al 1998). 
Such treatment may also lead to abnormalities in liver func-
tion. Anabolic steroids should therefore be regarded as an 
experimental treatment.
Other developmental therapies
There are a number of other compounds in the development 
stage that have either been designed or isolated. These 
modulate speciﬁ  c molecules that play critical roles in bone 
remodeling; the targets include c-src, cathepsin K and α2β3 
integrin receptor. The efﬁ  cacy of statins, thiazide diuretics, 
nitric oxide donors and isoﬂ  avones is still being debated and 
has yet to be established.
Monitoring of treatment
Once a commitment to treat a patient has been undertaken 
it is important to assess response to treatment. Treatment 
failure is said to have taken place when there are further 
fragility fractures despite adherence to treatment for one 
year and/or BMD declines below pre-treatment baseline 
(NICE document 87). Approximately 10%–15% of patients 
fail to respond to treatment (NOS 1998). Therefore, at least 
one repeat DXA scan is usually recommended to conﬁ  rm 
treatment response. Unfortunately, this has to be done after 
a minimum of two years of treatment, as it takes this long 
for response to anti-resorptive agents to exceed the least 
signiﬁ  cant change in BMD. Over a period of 2–3 years the 
BMD can be expected to increase approximately 5%–7% at 
the lumbar spine with bisphosphonate therapy. Taking into 
account this change, the precision of 1%–2% for a typical 
DXA scanner (Blake and Fogelman 2005) and the coefﬁ  cient 
of variation means that the least signiﬁ  cant change that can 
be detected is somewhere between 4.4% and 6.9% depending 
on the site (Cummings et al 2000). Therefore, it will take at 
least 2 years for a sufﬁ  ciently large change to have taken place 
to be sure that the result is a true representation of treatment 
response. Furthermore, the BMD may fall in the ﬁ  rst year 
of treatment only to subsequently gain in the second year: a 
phenomenon known as regression to the mean (Eastell and 
Bainbridge 2001).
The use of BMD has the disadvantages of taking two 
years before a lack of response will be noted and also the 
spine can be affected by degenerative changes, especially Clinical Interventions in Aging 2007:2(4) 534
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in patients over 65. An alternative is to use bone turnover 
markers, which have a maximum suppression in the order 
of 50% within three months of starting therapy (Eastell and 
Bainbridge 2001). This would allow earlier identiﬁ  cation of 
non-responders, but they can be difﬁ  cult to collect, tend to be 
very variable and are inﬂ  uenced by many factors. For exam-
ple a recent fracture will cause them to increase and they vary 
with meals and the time of day. It is therefore important to 
collect them at the same time of day. Nevertheless, they have 
been shown to predict further fracture and BMD response. 
The development of more reliable serum markers has made 
their use easier. They are increasingly being used to assess 
early response to treatment and compliance by measuring at 
baseline and 3–6 months after initiation of treatment.
At risk individual identified, eg, low trauma fracture  
DXA scan 
Normal: 
reassure 
Osteopenia  Osteoporotic
No fractures: 
lifestyle advice 
Fractures
Investigate and treat secondary causes. 
Baseline bone turnover markers 
First line treatment bisphosphonates, eg, alendronate, unless 
contraindicated. Add in calcium and vitamin D supplementation if 
low intake suspected or confirmed. 
Repeat bone turnover markers 3–6 months later and repeat DXA 
after 2 years. If response poor consider changing to alternative 
treatment. Allow 6 months washout if changing from a 
bisphosphonates to teriparatide.
Figure 9 Proposed ﬂ  ow chart for the treatment of men with osteoporosis.Clinical Interventions in Aging 2007:2(4) 535
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Conclusion
Osteoporotic fractures are a major public health problem in 
men and further work is required to clarify the pathogenesis 
of the condition. Despite the plethora of new and effective 
treatments for women there is very little evidence for their 
use in men. Studies are urgently required to address this issue. 
A possible treatment strategy using the currently available 
evidence is shown: Figure 9. The at risk individual, once 
identiﬁ  ed, should have a baseline DXA and investigations 
for secondary causes undertaken including bone turnover 
markers. Underlying secondary causes of osteoporosis should 
be treated where possible, whereas BPs are probably the 
treatment of choice in other men with osteoporosis. If these 
are contra-indicated or ineffective, teriparatide or alternatives 
such as strontium should be considered. Calcium and vita-
min D supplements may be useful in frail, elderly men with 
osteoporosis, who are likely to have vitamin D deﬁ  ciency and 
secondary hyperparathyroidism. In the case of BPs, repeating 
the bone turnover markers 3 to 6 months later could then be 
used to assess response to therapy and compliance. A DXA 
scan should be repeated 2 years later. It is hoped that further 
research will see more treatments licensed for use in men and 
new agents become available.
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